Project 3 ADM
Project 3 ADM
批准号:
10762126
负责人:
THOMAS D. SCHMITTGEN
金额:
$11.6万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
未结题
起止时间:
2018-09-17 至 2026-08-31
关键词:
3-DimensionalATAC-seqAcinar CellAcinus organ componentAddressAfrican AmericanAfrican American populationBlack PopulationsBlack raceCaliforniaCancer cell lineCaringCell LineCell ReprogrammingCellsChronicCoculture TechniquesCollagenConditioned Culture MediaDataDevelopmentDiseaseDisparityDuct (organ) structureDuctal Epithelial CellEarly DiagnosisEarly treatmentEducationEventExperimental ModelsExtracellular MatrixFibronectinsFloridaFundingGenderGene ExpressionGenesGoalsHeterogeneityHispanicHispanic PopulationsHistone Deacetylase InhibitorHumanImmuneImmunofluorescence ImmunologicIn SituIncidenceIndividualInflammationInflammatoryInstitutionLatinoLatino PopulationLesionLinkMacrophageMalignant NeoplasmsMalignant neoplasm of pancreasMetabolic stressMetaplasiaMethodsMicroscopicMolecularNormal RangeOutcomeOxidative StressPancreasPancreatic Ductal AdenocarcinomaPathway interactionsPatientsPenetrationPeptide HydrolasesPharmaceutical PreparationsPhenotypePilot ProjectsProcessPrognosisPublishingRaceRoleSamplingStainsStromal CellsSystemTissuesTrichostatin Aanticancer researchbiophysical propertiesbiophysical techniquescancer health disparitychronic pancreatitiscombatcomorbidityeffective therapyhealth equityimprovedinhibitorirritationmortalitymouse modelnovelpancreas developmentpancreatic ductal adenocarcinoma modelpancreatic metaplasiapancreatic stellate cellpharmacologicpreventracial disparitystellate celltherapeutic targettranscriptome sequencingtreatment responsetumor microenvironment
中文摘要
点击翻译按钮获取中文摘要
英文摘要
ABSTRACT – FULL PROJECT 3
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most devastating cancers with poor prognosis
and rising incidence. To combat this deadly disease, we should direct our efforts towards preventing PDAC or
halting the progression of precursor lesions to invasive disease parallel to developing novel treatments. One of
the earliest known initiating events for PDAC is the process of acinar-to-ductal metaplasia (ADM).
Understanding and reduction of ADM formation may reduce early PDAC development and progression. Blacks
display a significantly increased incidence and mortality from PDAC compared to other races for unknown
reasons. The role of race on pancreatic ADM and its contributions to the development and progression of
PDAC need to be addressed. In our previous studies, we used normal pancreatic acinar tissues from Black,
White and Hispanic donors to study the impact of race on acinar-to-ductal metaplasia (ADM) and found that
Blacks undergo ADM to a greater extent than Whites or Hispanics. In this competitive renewal, we will expand
on and extend our previous study by including diseased tissues from CP and PDAC from White, Black, and
Hispanic donors since accumulating evidence suggest that chronic pancreatitis (CP) is a major precursor to the
development of PDAC. We will investigate the impact of race on the cellular and molecular events regulating
the interplay between ADM and the microenvironment. Guided by our published and unpublished results, we
hypothesize that the racial disparities seen in PDAC are related to differences in how the pancreas
microenvironment develops during ADM, which means that ADM and its surrounding microenvironment can be
used as a target to treat PDAC. We propose the following specific aims to address this hypothesis: Aim 1: The
impact of race on ADM from the healthy pancreas, CP, and PDAC tissues. Aim 2: The roles of pancreatic
stellate cells and macrophages in ADM and ADM reversal. Aim 3: Contributions of the race to ADM reversal
and cell heterogeneity. The proposed studies will impact the field of pancreatic cancer by providing a missing
link between disparities, ADM, tumor microenvironment, and potential treatments for CP and PDAC. The
specific focus on the racial contributions of microenvironment remolding during pancreatic metaplasia aligns
with the Florida-California Cancer Research, Education and Engagement (CaRE2) Health Equity Center’s
overall goal to eliminate cancer health disparities among Blacks and Latinos in California, Florida, and across
the U.S..
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
R21 MPI microRNA directed therapy for treating early stage pancreatic cancer
-
批准号:10577609
-
项目类别:
-
资助金额:$17.82万
-
财政年份:2023
-
负责人:THOMAS D. SCHMITTGEN
-
依托单位:
Pilot Project 3: Contribution of Racial Disparity towards the Early Development of Pancreatic Cancer
-
批准号:10006214
-
项目类别:
-
资助金额:$11.3万
-
财政年份:2018
-
负责人:THOMAS D. SCHMITTGEN
-
依托单位:
miRNA Biomarkers for Hepatocellular Carcinoma Associated with Viral Hepatitis
-
批准号:8520269
-
项目类别:
-
资助金额:$16.77万
-
财政年份:2012
-
负责人:THOMAS D. SCHMITTGEN
-
依托单位:
miRNA Biomarkers for Hepatocellular Carcinoma Associated with Viral Hepatitis
-
批准号:8364566
-
项目类别:
-
资助金额:$25.1万
-
财政年份:2012
-
负责人:THOMAS D. SCHMITTGEN
-
依托单位:
Real-time PCR expression profiling of microRNA
-
批准号:7137111
-
项目类别:
-
资助金额:$21.02万
-
财政年份:2006
-
负责人:THOMAS D. SCHMITTGEN
-
依托单位:
Real-time PCR expression profiling of microRNA
-
批准号:7632039
-
项目类别:
-
资助金额:$20.92万
-
财政年份:2006
-
负责人:THOMAS D. SCHMITTGEN
-
依托单位:
Real-time PCR expression profiling of microRNA
-
批准号:7596042
-
项目类别:
-
资助金额:$20.92万
-
财政年份:2006
-
负责人:THOMAS D. SCHMITTGEN
-
依托单位:
Real-time PCR expression profiling of microRNA
-
批准号:7808845
-
项目类别:
-
资助金额:$20.91万
-
财政年份:2006
-
负责人:THOMAS D. SCHMITTGEN
-
依托单位:
Micro RNA Expression and Cancer
-
批准号:6764682
-
项目类别:
-
资助金额:$13.46万
-
财政年份:2004
-
负责人:THOMAS D. SCHMITTGEN
-
依托单位:
Micro RNA Expression and Cancer
-
批准号:6895843
-
项目类别:
-
资助金额:$13.46万
-
财政年份:2004
-
负责人:THOMAS D. SCHMITTGEN
-
依托单位:
APTAMERS AS CELLULAR TARGETING AGENTS
-
批准号:2839727
-
项目类别:
-
资助金额:$14.1万
-
财政年份:1999
-
负责人:THOMAS D. SCHMITTGEN
-
依托单位:
APTAMERS AS CELLULAR TARGETING AGENTS
-
批准号:6174299
-
项目类别:
-
资助金额:$14.15万
-
财政年份:1999
-
负责人:THOMAS D. SCHMITTGEN
-
依托单位:
5FLUOROURACIL EFFECTS ON URACIL-RICH MRNA STABILITY
-
批准号:2012360
-
项目类别:
-
资助金额:$10.32万
-
财政年份:1997
-
负责人:THOMAS D. SCHMITTGEN
-
依托单位:
ANTICANCER DRUG EFFECTS ON RNA PROCESSING
-
批准号:2105844
-
项目类别:
-
资助金额:$2.99万
-
财政年份:1995
-
负责人:THOMAS D. SCHMITTGEN
-
依托单位:
ANTICANCER DRUG EFFECTS ON RNA PROCESSING
-
批准号:2105843
-
项目类别:
-
资助金额:$2.86万
-
财政年份:1994
-
负责人:THOMAS D. SCHMITTGEN
-
依托单位:
Pilot Project
-
批准号:9788341
-
项目类别:
-
资助金额:$2.23万
-
财政年份:--
-
负责人:THOMAS D. SCHMITTGEN
-
依托单位:
Pilot Project 3: Contribution of Racial Disparity towards the Early Development of Pancreatic Cancer
-
批准号:10006223
-
项目类别:
-
资助金额:$2.18万
-
财政年份:--
-
负责人:THOMAS D. SCHMITTGEN
-
依托单位:
Pilot Project 3: Contribution of Racial Disparity towards the Early Development of Pancreatic Cancer
-
批准号:9634749
-
项目类别:
-
资助金额:$9.68万
-
财政年份:--
-
负责人:THOMAS D. SCHMITTGEN
-
依托单位:
国内基金
海外基金
登录
查看更多内容
基于ATAC-seq与DNA甲基化测序探究染色质可及性对莲两生态型地下茎适应性分化的作用机制
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:
-
依托单位:
利用ATAC-seq联合RNA-seq分析TOP2A介导的HCC肿瘤细胞迁移侵
袭的机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:柳静
-
依托单位:
面向图神经网络ATAC-seq模体识别的最小间隔单细胞聚类研究
-
批准号:62302218
-
项目类别:青年科学基金项目
-
资助金额:30.00万元
-
批准年份:2023
-
负责人:张双全
-
依托单位:
基于ATAC-seq策略挖掘穿心莲基因组中调控穿心莲内酯合成的增强子
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:黄铭坤
-
依托单位:
基于单细胞ATAC-seq技术的C4光合调控分子机制研究
-
批准号:32100438
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.0万元
-
批准年份:2021
-
负责人:涂晓雨
-
依托单位:
基于ATAC-seq技术研究交叉反应物质197调控TFEB介导的自噬抑制子宫内膜异位症侵袭的分子机制
-
批准号:82001520
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:汤小晗
-
依托单位:
靶向治疗动态调控肺癌细胞DNA可接近性的ATAC-seq分析
-
批准号:81802809
-
项目类别:青年科学基金项目
-
资助金额:21.0万元
-
批准年份:2018
-
负责人:蔡梅春
-
依托单位:
运用ATAC-seq技术分析染色质可接近性对犏牛初级精母细胞基因表达的调控作用
-
批准号:31802046
-
项目类别:青年科学基金项目
-
资助金额:27.0万元
-
批准年份:2018
-
负责人:张龚炜
-
依托单位:
基于ATAC-seq和RNA-seq研究CWIN调控采后番茄果实耐冷性作用机制
-
批准号:31801915
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2018
-
负责人:茹磊
-
依托单位:
基于ATAC-seq高精度预测染色质相互作用的新方法和基于增强现实的3D基因组数据可视化
-
批准号:31871331
-
项目类别:面上项目
-
资助金额:59.0万元
-
批准年份:2018
-
负责人:张治华
-
依托单位: